VALN - Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference | Benzinga
Saint-Herblain (France), November 7, 2023 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Jefferies London Healthcare Conference, to take place November 14-16, 2023 in London, UK.
Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will host a fireside chat at 2:30pm GMT on November 14 to discuss Valneva's commercial business and pipeline of infectious disease vaccines. This includes VLA1553, which has a U.S. Food and Drug Administration (FDA) PDUFA action date at the end of November 2023 and may, if approved, become the first licensed chikungunya vaccine; and VLA15, the Company's Lyme vaccine candidate, currently in Phase 3 clinical development and partnered with Pfizer Inc. (NYSE:PFE).
The live webcast of the fireside chat can be accessed here. A replay of the webcast will be available following the live events in the "Investor" section of the Valneva website at www.valneva.com. To request a meeting at the event, please contact your representative at Jefferies.
About Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical ...